Press Release
SOURCE: Incara Pharmaceuticals Corporation
Incara CEO Interview Regarding Initiation of Phase 2/3 Clinical Trial for OP2000 Available on CEOcast.com
RESEARCH TRIANGLE PARK, N.C., Jan. 31 /PRNewswire/ --
Incara Pharmaceuticals Corporation (Nasdaq: INCR - news) President and CEO, Clayton I. Duncan, will be interviewed for the website Ceocast.com to discuss the initiation of a Phase 2/3 clinical trial for OP2000 in ulcerative colitis patients. OP2000 is a subcutaneously administered ultra-low molecular weight heparin being developed by Incara and Elan Corporation, plc. The audio interview will be available over the internet at www.ceocast.com as of approximately 11:00 am on February 1, 2001.
The recently begun clinical trial is designed to enroll approximately 270 patients with symptoms of active ulcerative colitis. Patients will be treated with drug or placebo once a day for six weeks. The objective of treatment will be to cause complete remission or significantly improve the signs and symptoms of ulcerative colitis. If the results of this trial are positive, the trial is expected to serve as one of two pivotal safety and efficacy trials required for approval.
Incara Pharmaceuticals Corporation (http://www.incara.com ) is developing a diversified portfolio of proprietary therapies oriented to treatment of diseases afflicting large patient populations. In addition to OP2000, the Company's current programs include liver stem and precursor cell therapy for the treatment of liver failure, and small molecule catalytic antioxidants for treatment of stroke and cardiac reperfusion injury.
The statements in this press release that are not purely statements of historical fact are forward-looking statements, and actual results might differ materially from those anticipated. These statements and other statements made elsewhere by the Company or its representatives, which are identified or qualified by words such as ``intends,'' ``likely,'' ``will,'' ``suggests,'' ``expects,'' ``might,'' ``may,'' ``believe,'' ``could,'' ``should,'' ``would,'' ``anticipates,'' or ``plans,'' or similar expressions, are based on a number of assumptions that are subject to risks and uncertainties. Important factors that could cause results to differ include risks associated with the need to obtain funds for operations, uncertainties of scientific research, clinical trials and product development activities. These and other important risks are described in Incara's most recent registration statement on Form S-1 and its reports on Form 10-K, Form 10-Q and Form 8-K filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update the information in this release.
SOURCE: Incara Pharmaceuticals Corporation |
